Abstract
Two recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62Llow inflammatory eosinophils (iEos) and identified an intriguing correlation between such iEos and asthma control scores. Moreover, CD62Llow iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs.
Tweetable abstract
Patients with severe eosinophilic asthma (SEA) have an increased proportion of a subtype of eosinophils, CD62Llow inflammatory eosinophils (iEos), which are reduced after mepolizumab treatment. iEos might represent a novel useful biomarker in SEA.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients. Clin Exp Allergy. 2023;53(1):78–87.
doi: 10.1111/cea.14153 - 2. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295.
doi: 10.1172/JCI85664 - 3. Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab. Allergy. 2023;78(12):3154–3165.
doi: 10.1111/all.15909 - 4. Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis. Pediatr Allergy Immunol. 2021;32(3):465–478.
doi: 10.1111/pai.13403 • Offers sound data on the predictive power of blood eosinophil count on the risk of acute asthma exacerbations. - 5. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700.
doi: 10.1183/09031936.00162414 - 6. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
doi: 10.1164/rccm.201104-0597OC - 7. . Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233.
doi: 10.1007/s12016-018-8712-1 • Thorough perspective on asthmatic phenotypes and endotypes, which are essential to understand the importance of discovering novel biomarkers. - 8. . 2023 GINA report for asthma. Lancet Respir Med. 2023;11(7):589.
doi: 10.1016/S2213-2600(23)00230-8 - 9. Impact of blood eosinophil variability in asthma: a real-life population study. Ann Am Thorac Soc. 2022;19(3):407–414.
doi: 10.1513/AnnalsATS.202103-409OC - 10. Blood eosinophils subtypes and their survivability in asthma patients. Cells. 2020;9(5):1248.
doi: 10.3390/cells9051248 - 11. Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(2):155–162.
doi: 10.1164/rccm.202301-0149OC •• The first article that compares iEos in asthmatic patients versus patients with chronic obstructive pulmonary disease. - 12. . Eosinophil development, disease involvement, and therapeutic suppression. Adv Immunol. 2018;138:1–34.
doi: 10.1016/bs.ai.2018.03.001 • Thorough perspective on eosinophil biology, physiopathology and therapeutic aspects of eosinophil-mediated diseases. - 13. . Eosinophilic esophagitis: a review. JAMA. 2021;326(13):1310–1318.
doi: 10.1001/jama.2021.14920 - 14. . Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev. 2023;22(1):103219.
doi: 10.1016/j.autrev.2022.103219
